Currently, specific inhibitors against BER proteins such as Polβ, PNKP, FEN1, Ligase IIIα, and PARP1/PARG have been developed either to sensitize several cancers or to form synthetic lethal partnerships with common cancer mutations (reviewed in Grundy and Parsons, 2020). The gene discussed is FEN1; the disease is cancer.